Short-term effectiveness and potential factors of ustekinumab based on real-world data in Chinese psoriasis patients
CONCLUSION: In this study, nearly one-third of patients achieved PASI 75 after only the first-dose ustekinumab treatment. Sex, family history of psoriasis, MS, serum TG level might affect the short-term effectiveness, and serum HDL-C level may be a potential factor. The possibility of achieving treatment goals (PASI 75/90/100) at week 4 increased along with serum HDL-C levels.PMID:38531383 | DOI:10.1080/09546634.2024.2321188
Source: Journal of Dermatological Treatment - Category: Dermatology Authors: Xingyu Li Xiaowen Xie Jiashuai Li Jingjin Hu Kun Hu Minjia Tan Jing Yang Sichun Deng Yijie Liu Mi Zhang Yehong Kuang Junchen Chen Liqiu Liao Wu Zhu Source Type: research
More News: China Health | Cholesterol | Dermatology | Laboratory Medicine | Metabolic Syndrome | Psoriasis | Skin | Stelara | Study